Remibrutinib in everyday care for adults with chronic spontaneous urticaria in Germany
Observes how remibrutinib works and its safety in people with chronic spontaneous urticaria.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)
- Status
- Recruiting
- People taking part
- 470 people, planned
- Started
- 4 Aug 2026
- Expected to end
- 31 May 2029
- Type of study
- Observational, 2 groups
- Record updated
- 7 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic spontaneous urticaria (CSU, long-lasting hives with no known trigger). Their doctor must already have decided to switch them to remibrutinib.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Primary CSU confirmed by the treating doctor. Cohort 2: CSU not well controlled despite licensed or increased doses of sgH1-AH (second-generation antihistamines).
- Earlier treatment
- Cohort 2: only sgH1-AH before, with first generation H1-AH also allowed. Cohort 3: any other treatment in addition to H1-AH at any time, including continuous steroids for at least 3 weeks. Occasional steroid rescue medicine does not decide the cohort. People who ever had remibrutinib cannot join.
Main reasons for not taking part
- Taking part in any investigational trial, or in another Novartis-sponsored non-interventional study with remibrutinib
- Being in the safety follow-up phase of an earlier study
- Having had remibrutinib at any time before
- Not able or willing to enter diary data electronically for the whole study
- Getting remibrutinib outside of the local label
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- 7.2.1 Inclusion criteria Patients must meet all the following criteria to be eligible for inclusion in this study
- Patients with a confirmed diagnosis of primary CSU by the treating physician
- Aged at least 18 years on the date of enrollment
- Written informed consent of the patient to participate in the study and willingness to complete full follow-up period of 24 months
- Cohort-specific observational inclusion criteria:; Cohort 2: Inadequate control of CSU despite licensed dose or escalated sgH1-AH(s) (no other pre-treatment with exception of first generation H1-AH permitted) with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label; Cohort3: Any other treatment received in addition to H1-AH, any time during patients' CSU treatment history, with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label. Note, occasional steroid rescue medication is out of scope for cohort definition. If a patient had been on continuous steroids for at least 3 weeks during treatment history, they will be included in cohort 3
Who cannot take part
- Patients within the safety follow-up phase of a previous interventional or non-interventional study
- Patients who received remibrutinib at any time in the past
- Patients who are treated with remibrutinib outside of the local label
- Patients are excluded if they meet any of the following criteria:
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with remibrutinib
- Patients not capable or willing to continuously provide ePRO/eDiary data via electronic means throughout the duration of the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.
The 2 groups in the trial
- Cohort 2
Inadequate control of CSU despite licensed dose or escalated sgH1-AH(s) (no other pre-treatment with exception of first generation H1-AH permitted) with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label. Baseline visit comprises of clinical assessment while treated with sgH1-AH (i.e., preescalation to remibrutinib) and follow-up visits capture clinical outcome of escalated treatment with remibrutinib as per local label.
- Cohort 3
Any other treatment received in addition to H1-AH, any time during patients CSU treatment history, with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label. Baseline visit comprises of clinical assessment before switch to remibrutinib and follow-up visits capture clinical outcome of treatment with remibrutinib as per local label. Enrollment will be capped at a maximum of 30% of the local population.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Remibrutinib in Real-world Clinical Practice: a Prospective, Multi-country, Non-interventional, Effectiveness and Safety Study (REASSERT) - Local Adaptation in Germany From Global Umbrella Protocol (CLOU064A2402)
- Plain-language title
- Remibrutinib in everyday care for adults with chronic spontaneous urticaria in GermanyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 7 August 2026